July's CPI report may show a 3.3% increase, up from June's 3.0% reading. I believe inflation will likely rise in the coming months due to higher energy and food costs. So, I used...
Earnings season continues, with healthcare companies set to report next week Among them is Pfizer, whose stock has corrected significantly of late Based on the company's strong...
Stagflation remains one of the primary risks for the global economy in 2023. The stock market’s trajectory will continue to be dictated by worries over persistently high...
Stocks surged in July, with the major indexes enjoying their best gains since 2020. But the market is still off substantially for the year. The rally came despite the Federal...
The COVID-19 pandemic highlighted the importance of health care and the role biopharma companies play in drug and vaccine development. As a result, the sector grew tremendously...
Biotechnology stocks represent companies that research, develop or market healthcare-related therapies or products. They typically use living organisms, biological systems, or...
ABBV faces a significant loss of revenue beginning in 2023 from Humira biosimilars For now, the company is turning in steady earnings growth Wall Street consensus outlook is...
After its more than 450% surge during 2020, the meteoric rally in Moderna (NASDAQ:MRNA) shares continues this year. The gains—propelled by the biotech's breakthrough vaccine...
Vaccines manufactured by three groups have so far been approved in the UK. They include:AstraZeneca (LON:AZN) (NASDAQ:AZN)/ Oxford University; BioNTech (NASDAQ:BNTX) / Pfizer...
Kite, a unit of Gilead Sciences (GILD),has announced that theFDA has granted approval for its T cell immunotherapy Yescarta (axicabtagene ciloleucel) for a certain category of adults...
1
Up Again
0
Time to load up before the big rise coming next week
3
Classic pump n’ dump. What a shambles
1
Will reach above 95
5
when? hahah
0
Good time to accumulate.
1
Gilead will be supplying remdesivir to 127 countries starting next week! Also backed by big government organisations including donald trump. Good investmenr
2
High chance to be trading above 90, good long stock
4
By Deena Beasley(Reuters) - More than two-thirds of severely ill COVID-19 patients saw their condition improve after treatment with remdesivir, an experimental drug being developed by Gilead Sciences Inc., according to new data based on patient observation.The analysis, published on Friday by the New England Journal of Medicine, does not detail what other treatments the 61 hospitalized patients were given and data on eight of them were not included -- in one case because of a dosing error.